Progress and prospect of nanotechnology for cardiac fibrosis treatment
Interdisciplinary Medicine · 2023-10 · 1 (4)
DOI: 10.1002/inmd.20230018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Interdisciplinary Medicine, online erschienen am 05.09.2023. Verfasst von Samantha L Gaytan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USA. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, American Cancer Society, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Cardiac fibrosis is the excessive accumulation of extracellular matrix components in the heart, leading to reduced cardiac functionality and heart failure. This review provides an overview of the therapeutic applications of nanotechnology for the treatment of cardiac fibrosis. We first delve into the fundamental pathophysiology of cardiac fibrosis, highlighting the key molecular players, including Matrix Metalloproteinases, Transforming Growth Factor‐beta, and several growth factors, cytokines, and signaling molecules. Each target presents a unique opportunity to develop targeted nano‐therapies. We then focus on recent advancements in nanotechnology and how nanoparticles can be engineered to deliver drugs or therapeutic genes. These advanced delivery approaches have shown significant potential to inhibit fibrosis‐promoting factors, thereby mitigating the fibrotic response and potentially reversing disease progression. In addition, we discuss the challenges associated with developing and translating nanotechnology‐based drug delivery systems, including ensuring biocompatibility, safety, and regulatory compliance. This review highlights how nanotechnology can bridge the gap between lab research and clinical practice for treating cardiac fibrosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences School of Pharmacy The University of Texas El Paso El Paso Texas USA.
- Department of Interdisciplinary Health Sciences College of Health Sciences The University of Texas El Paso El Paso Texas USA.
- Department of Biomedical Engineering College of Engineering The University of Texas El Paso El Paso Texas USA.
- Center of Emphasis in Cancer Department of Molecular and Translational Medicine Paul L. Foster School of Medicine Texas Tech University Health Sciences Center El Paso El Paso Texas USA.
- Border Biomedical Research Center The University of Texas El Paso El Paso Texas USA.
ORCID-Profile: Md Nurunnabi
Förderung
- NIAID NIH HHS
- American Cancer Society
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Gaytan, S. L., Beaven, E., Gadad, S. S., & Nurunnabi, M. (2023). Progress and prospect of nanotechnology for cardiac fibrosis treatment. Interdisciplinary Medicine, 1(4). https://doi.org/10.1002/inmd.20230018
Vancouver
Gaytan SL, Beaven E, Gadad SS, Nurunnabi M. Progress and prospect of nanotechnology for cardiac fibrosis treatment. Interdisciplinary Medicine. 2023;1(4). doi:10.1002/inmd.20230018
BibTeX
@article{Gaytan2023,
author = {Gaytan, Samantha L and Beaven, Elfa and Gadad, Shrikanth S and Nurunnabi, Md},
title = {Progress and prospect of nanotechnology for cardiac fibrosis treatment},
journal = {Interdisciplinary Medicine},
year = {2023},
volume = {1},
number = {4},
doi = {10.1002/inmd.20230018}
}
EUVIMED